Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Cardiovascular risks associated with protease inhibitors for the treatment of HIV

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Safety and tolerability evaluation of erenumab for the preventive treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: In patients at high cardiovascular risk, the rate of events remains elevated despite traditional, evidence-based lipid-lowering therapy. Residual hypertriglyceridemia is an important contributor to this risk. However, prior medications with triglyceride-lowering effects have not reduced adverse clinical outcomes in the statin era.

AREAS COVERED: The present review summarizes evidence and recommendations related to triglyceride-lowering therapy in the primary and secondary preventive settings. We provide an overview of findings from recent meta-analyses, important observational studies, and a detailed description of landmark trials, including the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT). We further review recommendations from current guidelines.

EXPERT OPINION: Icosapent ethyl is a stable, highly purified ethyl ester of eicosapentaenoic acid that safely and effectively reduces cardiovascular events in the contemporary setting. It is prescribed at a dose of 2 grams twice daily and is indicated in patients at high cardiovascular risk who have fasting or non-fasting triglyceride levels ≥150 mg/dl despite maximally tolerated statin treatment, or in individuals with triglyceride levels ≥500 mg/dl. Conversely, omega-3 fatty acid preparations containing a combination of eicosapentaenoic acid and docosahexaenoic acid are not indicated for reduction of cardiovascular risk and should be actively deprescribed.

TidsskriftExpert Opinion on Drug Safety
Udgave nummer1
Sider (fra-til)31-42
Antal sider12
StatusUdgivet - 2022

ID: 66633532